[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Bionexus Gene Lab Corp (BGLC)

Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,371
  • Shares Outstanding, K 2,933
  • Annual Sales, $ 7,420 K
  • Annual Income, $ -2,980 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 4.17
  • Price/Sales 0.61
  • Price/Cash Flow N/A
  • Price/Book 0.47

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +22.13%
on 08/03/26
1.8800 -20.74%
on 08/17/26
+0.1700 (+12.88%)
since 07/31/26
3-Month
1.0700 +39.25%
on 06/10/26
2.7000 -44.81%
on 06/15/26
-0.8300 (-35.78%)
since 05/29/26
52-Week
1.0700 +39.25%
on 06/10/26
6.1000 -75.57%
on 09/25/25
-4.2800 (-74.18%)
since 08/28/25

Most Recent Stories

More News
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused...

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform

KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion...

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 ...

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) (

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology...

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC’s Biotech Footprint in Asia...

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision...

BGLC : 1.4900 (-3.87%)
BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a diversified...

BGLC : 1.4900 (-3.87%)

Business Summary

BioNexus Gene Lab Corp. is an emerging company in the business of selling chemical raw materials principally in the Southeast Asia region and the development of biopsy tests for early diagnosis and personalized health management. BioNexus Gene Lab Corp. is based in KUALA LUMPUR, Malaysia.

See More

Key Turning Points

3rd Resistance Point 1.5033
2nd Resistance Point 1.4967
1st Resistance Point 1.4933
Last Price 1.4900
1st Support Level 1.4833
2nd Support Level 1.4767
3rd Support Level 1.4733

See More

52-Week High 6.1000
Fibonacci 61.8% 4.1785
Fibonacci 50% 3.5850
Fibonacci 38.2% 2.9915
Last Price 1.4900
52-Week Low 1.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.